Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 28Genitourinary 13Breast 12Thoracic 8Other solid neoplasm 8Dermatologic 5Sarcoma 4Plasma cell 4Other hematologic neoplasm 4Tumor-Agnostic 3Gynecologic 3CNS 3Myeloid 2Lymphoid 2Other 1Head & Neck 1

Conditions

Melanoma 5Prostatic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Hydroxychloroquine × Dermatologic × Clear all
NCT04464759 2026-05-11

LIMIT

Abramson Cancer Center at Penn Medicine

Phase 1/2 Recruiting
94 enrolled
Dermatologic

Melanoma

NCT01480154 2026-04-13

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
62 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Prostatic Neoplasms

NCT00962845 2022-09-07

Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Rutgers, The State University of New Jersey

Phase EARLY_PHASE1 Completed
20 enrolled
Dermatologic

Melanoma

NCT03754179 2021-04-28

COMBI-R2

Universitair Ziekenhuis Brussel

Phase 1/2 Unknown
63 enrolled
Dermatologic

Melanoma

NCT01897116 2020-05-29

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
8 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡